Overexpression of interferon regulatory factor 7 (IRF7) reduces bone metastasis of prostate cancer cells in mice

Oncology Research

Volumn 25, Issue 4, 2017, Pages 511-522

  Yang, Zhao ^a   Chen, Wenxia ^a   Zhu, Weiliang ^a   Meng, Hui ^a   Chen, Jie ^a   Zhang, Jian ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Bone metastasis; Interferon regulatory factor 7 (IRF7); Prostate cancer

Indexed keywords

BETA INTERFERON; GELATINASE B; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 6; PROTEIN P53; VASCULOTROPIN A; SMALL INTERFERING RNA;

ADULT; ANIMAL CELL; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR GROWTH; UPREGULATION; ANIMAL; BONE TUMOR; CANCER GRADING; DISEASE MODEL; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; NATURAL KILLER CELL; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; RNA INTERFERENCE; SECONDARY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HETEROGRAFTS; INTERFERON REGULATORY FACTOR-7; INTERFERON-BETA; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; MALE; MICE; NEOPLASM GRADING; PROGNOSIS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 85018171209     PISSN: 09650407     EISSN: 15553906     Source Type: Journal    
DOI: 10.3727/096504016X14756226781802     Document Type: Article

References (28)

1. Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. New therapies for castration-resistant prostate cancer: Efficacy and safety. Eur Urol. 2011; 60: 279-90.
2. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010; 70: 875-82.
3. Sturge J, Caley MP, Waxman J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol. 2011; 8: 357-68.
4. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, Shimada N, Ohba Y, Takaoka A, Yoshida N, Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-7.
5. Li Q, Tang L, Roberts PC, Kraniak JM, Fridman AL, Kulaeva OI, Tehrani OS, Tainsky MA. Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. Mol Cancer Res. 2008; 6: 770-84.
6. Yang Y, Shaffer AL 3rd, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, Balasubramanian S, Mathews LA, Shinn P, Guha R, Ferrer M, Thomas C, Waldmann TA, Staudt LM. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-37.
7. Buckley NE, Hosey AM, Gorski JJ, Purcell JW, Mulligan JM, Harkin DP, Mullan PB. BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs. Mol Cancer Res. 2007; 5: 261-70.
8. Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012; 18: 1224-31.
9. Jin X, Kim SH, Jeon HM, Beck S, Sohn YW, Yin J, Kim JK, Lim YC, Lee JH, Kim SH, Kang SH, Pian X, Song MS, Park JB, Chae YS, Chung YG, Lee SH, Choi YJ, Nam DH, Choi YK, Kim H. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain 2012; 135: 1055-69.
10. Kim JK, Jin X, Ham SW, Lee SY, Seo S, Kim SC, Kim SH, Kim H. IRF7 promotes glioma cell invasion by inhibiting AGO2 expression. Tumour Biol. 2015; 36: 5561-9.
11. Wei T, Liu Q, He F, Zhu W, Hu L, Guo L, Zhang J. The role of N-acetylglucosaminyltransferases V in the malignancy of human hepatocellular carcinoma. Exp Mol Pathol. 2012; 93: 8-17.
12. Wei T, Li Y, Zhuo E, Zhu W, Meng H, Zhang J. Downregulation of GnT-V inhibits nasopharyngeal carcinoma cell CNE-2 malignancy in vitro and in vivo. Cancer Lett. 2011; 309: 151-61.
13. Ni J, Cozzi PJ, Hao JL, Beretov J, Chang L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, Kearsley JH, Li Y. CD44 variant 6 is associated with prostate cancer metastasis and chemo-/radioresistance. Prostate 2014; 74: 602-17.
14. Banyard J, Bao L, Hofer MD, Zurakowski D, Spivey KA, Feldman AS, Hutchinson LM, Kuefer R, Rubin MA, Zetter BR. Collagen XXIII expression is associated with prostate cancer recurrence and distant metastases. Clin Cancer Res. 2007; 13: 2634-42.
15. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Id- proteins expression in prostate cancer: High-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol. 2006; 19: 931-41.
16. Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer. Int J Urol. 2008; 15: 419-22.
17. Yuen HF, Chan YP, Cheung WL, Wong YC, Wang X, Chan KW. The prognostic significance of BMP-6 signaling in prostate cancer. Mod Pathol. 2008; 21: 1436-43.
18. Zhang L, Pagano JS. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol. 1997; 17: 5748-57.
19. Makovski V, Jacob-Hirsch J, Gefen-Dor C, Shai B, Ehrlich M, Rechavi G, Kloog Y. Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway. Cell Death Dis. 2014; 5: E1557.
20. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFNalpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol. 2006; 72: 1469-76.
21. Lee J, Wang A, Hu Q, Lu S, Dong Z. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice. Int J Oncol. 2006; 29: 1405-12.
22. Eiro N, Bermudez-Fernandez S, Fernandez-Garcia B, Atienza S, Beridze N, Escaf S, Vizoso FJ. Analysis of the expression of interleukins, interferon beta, and nuclear factor-kappa B in prostate cancer and their relationship with biochemical recurrence. J Immunother. 2014; 37: 366-73.
23. Lee SJ, Kang WY, Yoon Y, Jin JY, Song HJ, Her JH, Kang SM, Hwang YK, Kang KJ, Joo KM, Nam DH. Natural killer (NK) cells inhibit systemic metastasis of glioblastoma cells and have therapeutic effects against glioblastomas in the brain. BMC Cancer 2015; 15: 1011.
24. Hong ZF, Zhao WX, Yin ZY, Xie CR, Xu YP, Chi XQ, Zhang S, Wang XM. Natural killer cells inhibit pulmonary metastasis of hepatocellular carcinoma in nude mice. Oncol Lett. 2016; 11: 2019-26.
25. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004; 172: 2048-58.
26. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y. NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer. J Exp Med. 2004; 200: 1325-35.
27. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J Immunol. 2000; 165: 2665-70.
28. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J Immunol. 2007; 178: 7540-9.